Table 1.
Baseline patient characteristics*
| Placebo (n = 113) | Golimumab | |||
|---|---|---|---|---|
| 50 mg (n = 146) | 100 mg (n = 146) | Combined (n = 292) | ||
| Men, no. (%) | 69 (61) | 89 (61) | 86 (59) | 175 (60) |
| White, no. (%) | 110 (97) | 141 (97) | 142 (97) | 283 (97) |
| Age, years | 47.0 ± 10.6 | 45.7 ± 10.7 | 48.2 ± 10.9 | 47.0 ± 10.9 |
| PsA duration, years | 7.6 ± 7.9 | 7.2 ± 6.8 | 7.7 ± 7.8 | 7.5 ± 7.3 |
| No. of swollen joints (range 0–66) | 13.4 ± 9.8 | 14.1 ± 11.4 | 12.0 ± 8.5 | 13.0 ± 10.1 |
| No. of tender joints (range 0–68) | 21.9 ± 14.7 | 24.0 ± 17.1 | 22.5 ± 15.7 | 23.3 ± 16.4 |
| CRP level, mg/dl | 1.3 ± 1.6 | 1.3 ± 1.6 | 1.4 ± 1.8 | 1.3 ± 1.7 |
| HAQ DI score (range 0–3) | 1.03 ± 0.55 | 0.98 ± 0.65 | 1.05 ± 0.62 | 1.02 ± 0.64 |
| SF-36 PCS score (range 0–100) | 31.9 ± 9.3 | 33.0 ± 10.7 | 32.8 ± 8.9 | 32.9 ± 9.8 |
| SF-36 MCS score (range 0–100) | 47.6 ± 10.7 | 45.4 ± 12.2 | 45.0 ± 11.7 | 45.2 ± 12.0 |
| DAS28-CRP score | 4.9 ± 1.0 | 5.0 ± 1.1 | 4.9 ± 1.1 | 4.9 ± 1.1 |
| PASI score (range 0–72)† | 8.4 ± 7.4 | 9.8 ± 8.6 | 11.1 ± 9.5 | 10.4 ± 9.1 |
| Patients with fingers/toes with dactylitis, no. (%) | 38 (34) | 50 (34) | 49 (34) | 99 (34) |
| Patients with enthesitis, no. (%)‡ | 88 (78) | 109 (75) | 115 (79) | 224 (77) |
| Productivity score (0–10-cm VAS) | 5.3 ± 2.8 | 5.2 ± 2.9 | 5.6 ± 2.6 | 5.4 ± 2.8 |
*
Values are the mean ± SD unless otherwise indicated. PsA = psoriatic arthritis; CRP = C-reactive protein; HAQ = Health Assessment Questionnaire; DI = disability index; SF-36 = 36-item Short Form health survey; PCS = physical component summary; MCS = mental component summary; DAS28-CRP = 28-joint Disease Activity Score using the CRP level; PASI = Psoriasis Area and Severity Index; VAS = visual analog scale.
†
In patients with ≥3% of body surface area with psoriasis skin involvement.
‡
As determined using the PSA-modified Maastricht Ankylosing Spondylitis Enthesitis Score index.